V ancomycin has been a preferred agent for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections for over 50 years. 1 However, recently concerns have been raised as increased reports of vancomycin treatment failures have emerged. The development of heteroresistant vancomycinintermediate S. aureus isolates, which have been associated with complicated treatment courses and poor clinical outcomes, has been attributed to selective pressures resulting from the overutilization of vancomycin. 2 Vancomycin de-escalation may be a strategy to prevent the development of resistance without an adverse impact on clinical outcomes. The 2005 Infectious Diseases Society of America (IDSA) and American Thoracic Society (ATS) guidelines for the management of adults with hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and healthcareassociated pneumonia (HCAP) recom-mend the de-escalation of empirical antimicrobial therapy in accordance with available microbiological culture results and patient clinical response. 3 However, in many circumstances highquality lower respiratory tract cultures are unavailable or the finalized microbiological cultures have not resulted in growth of a causative pathogen, and clinicians are faced with deciding when antibiotics can be safely de-escalated on the basis of clinical response alone. The most recent HAP and VAP management guideline update (published in 2016) also suggests that empirical antibiotic therapy be deescalated rather than fixed but offers minimal guidance on the appropriate antibiotic deescalation approach. 4 There is a desperate need for strategies to improve antimicrobial utilization in modern healthcare settings, as antibiotic resistance has become one of the most significant threats of the current era. One strategy that has been considered a "game changer" in the diagnosis and management of infectious diseases is the use of rapid microbiological tests. 5 These tests can significantly influence patient care by enabling timely initiation and de-escalation of antimicrobial therapy, leading to optimal clinical and economic outcomes.
MRSA commonly colonizes the anterior nares, and assay-confirmed colonization has been recognized as a conceivable predictor of future clinical infection. 6, 7 The MRSA nares polymerase chain reaction (PCR) assay is a commercially available, rapid molecular surveillance technology for detecting MRSA nares colonization. 8 This assay detects a single staphylococcal target: the junction at which the staphylococcal cassette chromosome mec (SCCmec) integrates into the staphylococcal chromosome. 9 SCCmec is a genetic element that contains mecA, a gene that encodes penicillin binding protein 2A, which confers resistance to the b-lactam antibiotics. This assay is relatively inexpensive and readily available and has an average time from arrival in the laboratory to a definite result of 2 hours; this is
KEY POINTS

• Negative methicillin-resistant
Staphylococcus aureus (MRSA) screening of the anterior nares may be used to guide de-escalation of vancomycin in pulmonary infections.
• A protocol engaging pharmacists in the process of ordering MRSA screening and evaluating screening results may lead to reduced vancomycin days of therapy.
• The study described herein is believed to be the first of its kind to include a significant portion of patients with an acute exacerbation of chronic obstructive pulmonary disease.
significantly shorter than the average turnaround time for conventional cultures. 10 Multiple studies have evaluated the clinical utility of the MRSA PCR in predicting clinical MRSA infection in the lower respiratory tract. All evaluations consistently demonstrated robust negative predictive value (NPV) results, anywhere from 95.2% to 99.2%. [11] [12] [13] [14] [15] These data suggest that MRSA pneumonia is unlikely in the absence of MRSA nares colonization and that negative results can be reasonably used to guide the deescalation of empirical vancomycin therapy in patients with suspected lower respiratory tract infections. Surveillance of MRSA colonization for the purpose of vancomycin de-escalation has been previously described in a published observational cohort study. 16 However, in that analysis a MRSA PCR assay was not used. Instead, MRSA surveillance was done through nasal and posterior pharyngeal swabs inoculated onto either CHROMagar MRSA plates (Chromagar, Paris, France) or chromID MRSA plates (bioMérieux SA, Marcy-l'Étoile, France), which takes an additional 24-48 hours of incubation time and subsequently requires Staphaurex (Remel, Inc., Lenexa, KS) confirmatory testing.
Protocol development and implementation
Based on the strong body of literature supporting the NPV of the MRSA PCR assay in establishing the absence of MRSA in the lower respiratory tract, a MRSA surveillance protocol was developed as a part of an antimicrobial stewardship (AMS) program at St. Vincent's Medical Center Riverside. The AMS team consisted of physicians specialized in infectious diseases, microbiologists, infection control practitioners, and a dedicated AMS pharmacist. The protocol provided pharmacists the authority to order MRSA PCR nares screening without a direct physician order for patients who (1) were admitted to a medical or surgical unit, (2) received vancomycin for suspected or confirmed pulmonary infections, including HCAP, HAP, community-acquired pneumonia (CAP), or an acute exacerbation of chronic obstructive pulmonary disease (AECOPD), and (3) had not received nasal mupirocin during the hospital stay. Intensive care unit (ICU) patients were excluded from this protocol, because all patients admitted to an ICU at the institution received decolonization therapy with intranasal mupirocin, which may affect MRSA PCR sensitivity. A negative PCR result was not attributed to ongoing vancomycin therapy, as this antibiotic has been shown to seldom, if ever, influence S. aureus nasal colonization and to infrequently eradicate MRSA from the lower respiratory tract during the first 48 hours of treatment. 17 Upon receipt of all i.v. vancomycin orders, pharmacists were expected to dose and monitor vancomycin and determine patient eligibility for MRSA PCR screening. If a patient was deemed a candidate for screening, an order for a MRSA PCR intranasal swab assay was placed by a pharmacist in the electronic medical record. After insertion of a swab into each anterior nostril by nursing staff, swab specimens were returned to the microbiology lab, which performed PCR assays 24 hours per day and 7 days per week using the GeneXpert Xpert MRSA system (Ceph eid, Sunnyvale, CA). PCR results were then captured and displayed in the patient's electronic medical record. In addition, a realtime electronic patient surveillance system generated alerts prompting pharmacists to perform PCR results interpretation. Negative PCR results were then used to provide recommendations to prescribers for vancomycin deescalation. Pharmacist-conducted interventions relating to MRSA PCR assay findings were completed from 7 a.m. to 9 p.m. each day of the week. PCR results displayed after 9 p.m. were reviewed the following day due to limited overnight pharmacist availability. Upon protocol approval, extensive education regarding the utility of MRSA PCR surveillance was provided to the internal medicine, pulmonary, and infectious diseases medical services. The purpose of the study described here was to evaluate the impact of this pharmacist-driven MRSA surveillance protocol on the duration of vancomycin therapy and clinical outcomes in patients with lower respiratory tract infections.
Materials and methods
Patient selection. The study received institutional review board approval and was conducted at St. Vincent's Medical Center Riverside, a 528-bed nonprofit, tertiary community facility. It was a retrospective, quasi-experimental pre-post cohort study. Cases were identified by querying electronic medical records to generate a list of patients whose records contained an International Classification of Diseases, Ninth Revision (ICD-9) or ICD-10 code for HCAP, HAP, CAP, or AECOPD documented from September 2013 through February 2014 (the preprotocol period) or from September 2015 through February 2016 (the postprotocol period). For each of those time periods, a list of all patients who received i.v. vancomycin was generated. These lists were crossreferenced to identify only patients who had received vancomycin for the ICD-9 or ICD-10 code diagnoses of interest. Patients 18 years of age or older who had been admitted to a medical or surgical unit for at least 24 hours, had received at least 1 dose of vancomycin empirically for suspected or confirmed pneumonia or an AECOPD, and had received at least 72 hours of empirical antibiotic therapy were included in the study population. Patients were excluded if they were known to have been pregnant, incarcerated, or admitted to an ICU; if they had received intranasal mupirocin during hospitalization; or if they had required vancomycin for a concomitant infection (e.g., skin and soft tissue infection). Progress notes and culture results were reviewed to determine if patients had required vancomycin for a concomitant infection.
Data collection and outcomes. All clinical and demographic data were collected using the electronic medical record. Baseline data obtained included age, sex, height, weight, body mass index, temperature, and white blood cell count on day 1 of antimicrobial therapy, as well as baseline and discharge vital signs. Information on baseline factors that have been associated with an increased risk of multidrug-resistant infections were also collected; this information included whether or not the patient was positive for human immunodeficiency virus (HIV) infection, was immunocompromised, had received antimicrobial therapy within the preceding 90 days, had been hospitalized for 2 or more days within the preceding 90 days or was hospitalized for 5 or more days during the evaluated admission, had received home infusion therapy, had received chronic dialysis, or resided in a nursing home or extended-care facility. 3 Patients were categorized as immunocompromised if they had received 20 mg or more of prednisone daily for at least 14 days, had received biological agents in the preceding 30 days, had received cancer chemotherapy within the preceding 6 months, had received a solid organ transplant, or had HIV infection with a CD4+ count of ≤200 cells/mL. 18 The baseline rate of COPD was determined in order to determine the rate of AECOPD. If available, results of all microbiological blood and respiratory cultures (sputum, induced sputum, bronchoalveolar lavage, and bronchial wash) were collected.
The primary outcome was vancomycin days of therapy (DOT) before and after protocol implementation. DOT was chosen as the primary outcome because recent evidence sugests that DOT should be the preferred metric in the acute care setting. 19 Data on vancomycin DOT were collected from medication administration records; DOT was measured by assessing the date and time of the first vancomycin dose administered and the date and time of vancomycin order discontinuation.
Secondary outcomes evaluated included the quantity of vancomycin levels obtained, rate of clinical stability, rate of acute kidney injury (AKI) during vancomycin therapy, hospital length of stay (LOS), in-hospital mortality, and protocol compliance and utility. All clinical and demographic data were collected using electronic medical records. Clinical stability criteria were extrapolated from the 2007 IDSA-ATS consensus guidelines on the management of CAP in adults. 20 If patients met 2 of the following criteria by either 48 hours after the discontinuation of all antibiotics or before discharge, whichever came sooner, they were considered not to be clinically stable: (1) heart rate of ≥100 beats/min, (2) respiratory rate of ≥24 breaths/min, (3) systolic blood pressure of ≤90 mm Hg, (4) temperature of ≥37.8 °C, and (5) arterial oxygen saturation of ≤90%. To determine the rates of AKI in the 2 groups, serum creatinine levels were followed during vancomycin administration and for up to 48 hours after discontinuation to determine the rate of AKI per the RIFLE criteria, which are used to define stages of progressive deterioration in AKI (risk, injury, failure, loss of kidney function, and end-stage kidney disease). 21 LOS was defined as the interval from hospital admission to hospital discharge or death. In-hospital mortality was determined by referencing discharge notes to determine if a patient was alive at discharge. In addition, protocol compliance and utility were evaluated. It was determined that protocol compliance occurred if the MRSA PCR assay was ordered within 48 hours of the first vancomycin dose administered and deescalated within 24 hours of a negative MRSA PCR assay result.
Statistical analysis. Based on an estimated standard deviation of 3 days and a 2-sided alpha of 0.05, we estimated in an a priori calculation that samples of 150 patients in each group (300 patients in total) were required in order to achieve 80% power to detect a 1.5-day reduction in vancomycin DOT between groups. Continuous data were analyzed using Student's t test, and differences in proportions were analyzed using the chi-square test or Fisher's exact test as appropriate. Ordinal and non-normally distributed continuous data were analyzed using the Mann-Whitney U test. Data are expressed as medians with interquartile ranges or as numbers and percentages of patients, as appropriate. All data analysis was performed using SAS software (SAS Institute, Cary, NC). 22 
Results
Due to the small number of patients initially identified for inclusion in the preprotocol group, all patient records were reviewed sequentially according to date of admission until 150 patients were included in each study group. In total, 754 records were reviewed and 454 patients were excluded ( Figure 1 ). Baseline demographic data and clinical characteristics were similar in the preprotocol and postprotocol groups overall (Table 1) . Compared with the preprotocol group, the postprotocol group had a 2.1-day reduction in median vancomycin DOT (2.1 days versus 4.2 days, p < 0.0001), as shown in Figure 2 .
With regard to the secondary outcomes, fewer serum vancomycin levels were obtained in the postprotocol group versus the preprotocol group (median determinations per patient, 1 versus 2; p < 0.0001). No significant between-group differences were observed with respect to the percentage of patients reaching clinical stability, rate of AKI, LOS, and in-hospital mortality (Table 2) .
MRSA-positive cultures occurred more frequently in the preprotocol group than in the postprotocol group (9 of 150 patients [6%] versus 3 of 150 patients [2%]); however, the difference was not found to be statistically significant (p = 0.077). The overall rate of MRSA pneumonia in the study cohort was 4% (12 of 300 patients). In the postprotocol group, all 3 MRSApositive cultures originated from sputum specimens. In the preprotocol group, 7 MRSA-positive cultures were from the sputum and 2 were from the blood. Of the 150 patients in the postprotocol group, 118 (78.7%) had a screen ordered within 48 hours. A total of 134 PCR screens were ordered, 22 (16.4%) of which were positive. Only 1 patient with a negative PCR screen had MRSA growth in sputum and bronchial wash culture samples, indicating an NPV of 99.1% for the assay in the study cohort overall. There were no patients with vancomycin reinitiation after deescalation. Vancomycin therapy was not deescalated in the patient who had MRSA growth in cultures and a negative MRSA PCR assay. Incomplete compliance with the protocol was observed. Ninety-six of 118 screens that were ordered within 48 hours were negative and thus provided targets for deescalation. However, only 53 (55.2%) of the 96 negative screens resulted in deescalation within 24 hours. A subgroup analysis was performed in the postprotocol group to compare vancomycin DOT values between patients who had a MRSA PCR assay ordered within 48 hours and those who did not. The results of this subgroup analysis showed a 1.8-day reduction in vancomycin DOT among patients who had an assay ordered within 48 hours versus those who did not (median, 2.0 days versus 3.8 days; p = 0.0475), as shown in Figure 3 .
Discussion
MRSA lower respiratory tract infections are a significant cause of mortality and often require consideration of empirical antimicrobial therapy. 23 Despite MRSA's relatively low prevalence in pulmonary infections overall, the issue of how to define the patient population that warrants empirical use of anti-MRSA antibiotics remains controversial. 24 Even more elusive is an optimal approach for determining when it is appropriate to deescalate therapy in the event empirical anti-MRSA coverage is initiated without positive microbiological evidence. Strategies for improving antibiotic use and evidence for AMS best practices in this arena are greatly needed. MRSA colonizes the anterior nares, and colonization has been recognized as a conceivable predictor of future clinical infection. 6, 7 The MRSA PCR assay is a commercially available, rapid molecular surveillance technology with the ability to detect MRSA nares colonization. 8 Recent studies have evaluated the diagnostic utility of the MRSA PCR assay in guiding antimicrobial therapy in patients with suspected pneumonia. These studies have consistently shown that a negative nasal swab has a high NPV (>95%) for ruling out clinical infection due to MRSA in the lower respiratory tract. [11] [12] [13] [14] [15] Our overall cohort NPV of 99.1% for MRSA pneumonia was comparable to previous findings.
11 -15 This robust NPV suggests that MRSA pneumonia is unlikely in the absence of MRSA nasal colonization and that negative results can be reasonably used to guide deescalation of empirical anti-MRSA therapy. Our study demonstrated a statistically significant reduction in vancomycin DOT with the implementation of a pharmacist-driven MRSA surveillance protocol.
Here we describe a unique expansion of pharmacists' responsibilities and scope of practice to include ordering of cultures and interpretation of results, and we introduce an innovative method to decrease vancomycin utilization. Although not the subject of this study, cost reduction through reduction of antibiotic use, nurse medication administration time, and pharmacist time spent monitoring vancomycin therapy could be inferred from our results. Protocol implementation was associated with a reduction in the median quantity of vancomycin levels obtained per patient from 2 to 1 (p < 0.0001). Although current literature suggests that aggressive vancomycin dosing regimens aimed at achieving trough concentrations of 15-20 mg/mL, as recommended by IDSA-endorsed clinical practice guidelines, have increased the rate of nephrotoxicity, our study did not show that reducing vancomycin DOT decreased the rate of AKI. 25, 26 However, the study was likely underpowered to detect a difference given the low overall AKI event rate.
Our findings are supported by data from a recently published retrospective analysis by Baby et al. 27 showing that implementation of a similar pharmacist-driven, pragmatic approach to incorporating MRSA PCR into deescalation efforts reduced the mean duration of MRSA-targeted therapy by 46.6 hours. However, that study had a relatively small sample size, did not evaluate staff compliance with protocol requirements, and did not include the AECOPD population. Our study was perhaps unique in that 41% of the study population consisted of patients with an AECOPD; to our knowledge, this population has not previously been described in the context of the type of MRSA surveillance program described here.
Among other limitations, the retrospective, quasi-experimental design of our study did not involve random assignment. Our study only involved patients at a single community hospital. We did not account for alternative sites of MRSA colonization, and previous studies have found that the nares may not be the only relevant MRSA colonization screening sites 28 ; this may offer a possible explanation for the 1 case in our study in which MRSA PCR testing was negative but sputum and bronchial wash cultures were positive. It is noteworthy that the study results may not be generalizable to facilities with higher rates of MRSA pneumonia due to a conceivable proportional increase in positive MRSA PCR results, which would reasonably attribute to lower rates of vancomycin deescalation. The overall MRSA pneumonia rate of 4% in our cohort was relatively low in comparison to some previously described rates but comparable to other reported rates.
11
Incomplete staff compliance with the protocol was observed. Ninety-six of the 118 screens that were ordered within 48 hours were negative, thus identifying targets for deescalation. However, only 53 (55.2%) of those 96 negative screens resulted in vancomycin therapy deescalation within 24 hours. Despite relatively poor protocol compliance, our facility's efforts were successful in reducing vancomycin DOT. We feel that this finding is of particular importance, as real-life protocol implementation and compliance will not always be perfect. However, as demonstrated in this study, protocol implementation-even with incomplete compliance-can have a large impact on vancomycin utilization.
It must also be noted that a number of other AMS initiatives were implemented at our facility after the period during which patients in the preprotocol group were hospitalized but prior to protocol implementation. We hypothesized that the effect of other stewardship initiatives might confound the results of our primary outcome analysis. In order to address this concern, a subgroup analysis was performed in the postintervention group to evaluate vancomycin DOT when the assay was or was not ordered per protocol within 48 hours of the start of vancomycin therapy; this allowed the evaluation of patients hospitalized during the same time period with similar exposures to new AMS initiatives. Compared with patients for whom MRSA PCR assays were ordered per protocol, those for whom assays were not ordered per protocol had a 1.8-day reduction in median vancomycin DOT (2.0 days versus 3.8 days; p = 0.0475); this difference indicated that other AMS activities likely did not influence the primary outcome.
Conclusion
Among patients with suspected or confirmed pneumonia or an AECOPD, the expansion of pharmacists' traditional scope of practice to include a surveillance protocol using a MRSA PCR nares assay to guide vancomycin deescalation resulted in a reduction in vancomycin utilization without compromising clinical outcomes.
